Effects of inhibitors of FGFR3 on gene transcription

Details for Australian Patent Application No. 2006321602 (hide)

Owner Novartis AG

Inventors Masih-Khan, Esther; Moler, Edward; Stewart, Keith; Rowe, Michael; Trudel, Suzanne; Heise, Carla

Agent Davies Collison Cave

Pub. Number AU-B-2006321602

PCT Pub. Number WO2007/067968

Priority 60/748,944 08.12.05 US

Filing date 7 December 2006

Wipo publication date 14 June 2007

Acceptance publication date 8 March 2012

International Classifications

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

Event Publications

26 June 2008 PCT application entered the National Phase

  PCT publication WO2007/067968 Priority application(s): WO2007/067968

8 March 2012 Application Accepted

  Published as AU-B-2006321602

5 July 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006321607-Piezoelectric transducer signal processing circuit

2006321593-CTLA-4 antibody dosage escalation regimens